Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GRAIL Inc. (GRAL)
USD72.00
-3.79 (-5.00%)
US NASDAQ Healthcare Biotechnology
Address
1525 O’Brien Drive 94025
Menlo Park, CA, US
Menlo Park, CA, US
CEO
Robert Ragusa
Website
grail.com
IPO
2024-06-12
CIK 1699031 ISIN US3847471014
Description
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
News Sentiment (7d)
49 articles
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GRAL Newsfile Corp
- Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm GlobeNewsWire
- ROSEN, A LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL Globe News Wire
- INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead the Grail Class Action Lawsuit PRNewsWire
- GRAIL, Inc. (GRAL) Securities Class Action Filed Following NHS-Galleri Trial Failure and $2.2 Billion Market Cap Loss -- HBSS GuruFocus
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD72.00
-3.79 (-5.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
764.5K
Beta
3.16
Float Shares
34.65M
Free Float %
84.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.62% | -3.53% | +34.25% | -36.11% | -27.73% | -28.43% | +70.21% | +348.46% | +348.46% | +348.46% | +348.46% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
72.00
Low
56.00
-22.2%
Consensus
75.67
+5.1%
Median
65.00
-9.7%
High
130.00
+80.6%
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
56.00
-22.2%
|
| Last Quarter | 6 |
74.50
+3.5%
|
| Last Year | 11 |
86.09
+19.6%
|
| All Time | 12 |
81.58
+13.3%
|
Quality scores
Altman Z-Score
-0.14
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+17.2% ★ Q1'26: +28.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+82.5% ★ Q1'26: +26.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-163.2% Q1'26: -214.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-363.0% Q1'26: -332.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-30.2% Q1'26: -23.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15.2% Q1'26: +18.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.26× Q1'26: -0.13× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 7 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
125.60M
est: 122.26M (+2.7%)
|
147.17M
est: 146.94M (+0.2%)
|
180.16M
172.09M – 184.36M
+22.6% YoY
|
222.64M
204.13M – 249.37M
+23.6% YoY
|
283.56M
282.68M – 284.44M
+27.4% YoY
|
377.63M
351.65M – 408.23M
+33.2% YoY
|
492.53M
458.65M – 532.44M
+30.4% YoY
|
| EBITDA |
-610.17M
est: -122.26M (-399.1%)
|
-377.82M
est: -146.94M (-157.1%)
|
-180.16M
-184.36M – -172.09M
-22.6% YoY
|
-222.64M
-249.37M – -204.13M
-23.6% YoY
|
-283.56M
-284.44M – -282.68M
-27.4% YoY
|
-377.63M
-408.23M – -351.65M
-33.2% YoY
|
-492.53M
-532.44M – -458.65M
-30.4% YoY
|
| EBIT |
-768.22M
est: -122.26M (-528.4%)
|
-534.16M
est: -146.94M (-263.5%)
|
-180.16M
-184.36M – -172.09M
-22.6% YoY
|
-222.64M
-249.37M – -204.13M
-23.6% YoY
|
-283.56M
-284.44M – -282.68M
-27.4% YoY
|
-377.63M
-408.23M – -351.65M
-33.2% YoY
|
-492.53M
-532.44M – -458.65M
-30.4% YoY
|
| Net Income |
-2.03B
est: -1.91B (-5.9%)
|
-408.35M
est: -395.33M (-3.3%)
|
-400.56M
-420.46M – -380.65M
-1.3% YoY
|
-405.75M
-422.20M – -389.29M
-1.3% YoY
|
-484.88M
-485.94M – -323.35M
-19.5% YoY
|
-383.10M
-423.46M – -348.84M
+21.0% YoY
|
-351.49M
-388.52M – -320.06M
+8.3% YoY
|
| SGA |
367.82M
est: 734.79M (-49.9%)
|
275.80M
est: 883.17M (-68.8%)
|
1.08B
1.03B – 1.11B
+22.6% YoY
|
1.34B
1.23B – 1.50B
+23.6% YoY
|
1.70B
1.70B – 1.71B
+27.4% YoY
|
2.27B
2.11B – 2.45B
+33.2% YoY
|
2.96B
2.76B – 3.20B
+30.4% YoY
|
| EPS |
-63.54
est: -51.26 (-23.9%)
|
-11.11
est: -11.41 (+2.6%)
|
-10.72
-11.44 – -10.36
+6.0% YoY
|
-10.90
-11.49 – -10.59
-1.6% YoY
|
-10.30
-13.22 – -8.80
+5.4% YoY
|
-10.42
-11.52 – -9.49
-1.2% YoY
|
-9.56
-10.57 – -8.71
+8.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-250.24M
OE per share TTM
-6.95
Owner's Yield
-11.32%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
226.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
114
Total invested
82.45M
Insider transactions (90d)
0
Beneficial owners (>5%)
8
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Illumina, Inc. | 4.50M | 14.50% | 4.50M | — | 4.50M | — | CO | Delaware | 2024-08-14 | ↗ |
| 2 | Capital (Master), L.P. | 3.00M | 9.66% | — | 3.00M | — | 3.00M | PN | Cayman Islands | 2024-11-14 | ↗ |
| 3 | John Petry | 3.00M | 9.66% | 3.00M | — | 3.00M | — | IN | Cayman Islands | 2024-11-14 | ↗ |
| 4 | Sessa Capital GP, LLC | 3.00M | 9.66% | 3.00M | — | 3.00M | — | OO | Cayman Islands | 2024-11-14 | ↗ |
| 5 | Sessa Capital IM GP, LLC | 3.00M | 9.66% | 3.00M | — | 3.00M | — | OO | Cayman Islands | 2024-11-14 | ↗ |
| 6 | Sessa Capital IM, L.P. | 3.00M | 9.66% | 3.00M | — | 3.00M | — | PN | Cayman Islands | 2024-11-14 | ↗ |
| 7 | PRIMECAP Management Company | 2.18M | 7.03% | 2.15M | — | 2.18M | — | IA | 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 | 2024-11-12 | ↗ |
| 8 | CRCM Opportunity Fund III, LP | 397.4K | 1.28% | — | 397.4K | — | 397.4K | — | Delaware | 2024-08-30 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
114
-322 vs prev Q
New positions
14
Closed positions
321
Increased
38
Reduced
29
Put/Call ratio
0.00
Calls held
20.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 2.96M +493.5K (+20.0%) | 253.20M +107.5M (+73.7%) | 8.19% +1.158 pp | 0.00% +0.002 pp | USD40.67 +110.4% | 6 qtrs — |
| 2 | FARALLON CAPITAL MANAGEMENT LLC | 2.34M +993.7K (+73.7%) | 200.51M +120.7M (+151.4%) | 6.49% +2.637 pp | 0.95% +0.620 pp | USD68.70 +24.6% | 3 qtrs — |
| 3 | BAKER BROS. ADVISORS LP | 2.09M +455.2K (+27.9%) | 178.48M +82.1M (+85.2%) | 5.77% +1.123 pp | 1.05% +0.349 pp | USD32.64 +162.2% | 5 qtrs — |
| 4 | VANGUARD GROUP INC | 1.98M +163.8K (+9.0%) | 169.54M +62.1M (+57.8%) | 5.48% +0.300 pp | 0.00% +0.001 pp | USD28.12 +204.4% | 7 qtrs — |
| 5 | PRIMECAP MANAGEMENT CO/CA/ | 1.84M -182.3K (-9.0%) | 157.37M +37.9M (+31.7%) | 5.09% -0.675 pp | 0.12% +0.028 pp | USD14.83 +477.1% | 7 qtrs — |
| 6 | STATE STREET CORP | 1.83M +510.5K (+38.8%) | 156.42M +78.5M (+100.9%) | 5.06% +1.302 pp | 0.01% +0.003 pp | USD38.21 +124.0% | 7 qtrs — |
| 7 | MORGAN STANLEY | 1.51M +588.6K (+63.8%) | 129.39M +74.8M (+137.1%) | 4.18% +1.552 pp | 0.01% +0.004 pp | USD57.48 +48.9% | 7 qtrs — |
| 8 | CRCM LP | 1.07M -770.3K (-41.8%) | 91.78M -17.2M (-15.8%) | 2.97% -2.288 pp | 31.01% -0.511 pp | USD14.24 +501.1% | 7 qtrs — |
| 9 | ARBITER PARTNERS CAPITAL MANAGEMENT LLC | 1.04M -300.0 (0.0%) | 88.64M +27.4M (+44.7%) | 2.87% -0.088 pp | 43.20% +6.621 pp | USD18.81 +355.0% | 7 qtrs — |
| 10 | DEEP TRACK CAPITAL, LP | 1.02M +1.0M (+100.0%) | 87.54M +87.5M (+100.0%) | 2.83% +2.831 pp | 1.56% +1.561 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 853.1K +213.5K (+33.4%) | 73.02M +35.2M (+93.1%) | 2.36% +0.537 pp | 0.01% +0.004 pp | USD53.16 +61.0% | 6 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 801.5K +71.3K (+9.8%) | 68.61M +25.4M (+58.9%) | 2.22% +0.136 pp | 0.00% +0.002 pp | USD34.18 +150.4% | 7 qtrs — |
| 13 | BANK OF AMERICA CORP /DE/ | 708.5K +373.1K (+111.3%) | 60.64M +40.8M (+205.8%) | 1.96% +1.005 pp | 0.00% +0.003 pp | USD66.13 +29.4% | 7 qtrs — |
| 14 | GOLDMAN SACHS GROUP INC | 537.0K +172.0K (+47.1%) | 45.96M +24.4M (+112.9%) | 1.49% +0.445 pp | 0.01% +0.003 pp | USD64.74 +32.2% | 6 qtrs — |
| 15 | ALYESKA INVESTMENT GROUP, L.P. | 442.5K +442.5K (+100.0%) | 37.87M +37.9M (+100.0%) | 1.22% +1.225 pp | 0.11% +0.107 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 16 | RA CAPITAL MANAGEMENT, L.P. | 428.3K +428.3K (+100.0%) | 36.66M +36.7M (+100.0%) | 1.19% +1.186 pp | 0.38% +0.376 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 17 | SESSA CAPITAL IM, L.P. | 364.7K -421.4K (-53.6%) | 31.22M -15.3M (-32.8%) | 1.01% -1.233 pp | 0.58% -0.517 pp | USD14.74 +480.7% | 7 qtrs — |
| 18 | NORTHERN TRUST CORP | 341.4K +945.0 (+0.3%) | 29.22M +9.1M (+45.2%) | 0.95% -0.026 pp | 0.00% +0.001 pp | USD35.32 +142.3% | 7 qtrs — |
| 19 | AQR CAPITAL MANAGEMENT LLC | 326.8K -95.8K (-22.7%) | 27.86M +3.6M (+14.6%) | 0.90% -0.301 pp | 0.01% -0.001 pp | USD19.29 +343.7% | 7 qtrs — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 270.8K +19.3K (+7.7%) | 23.18M +8.3M (+55.9%) | 0.75% +0.032 pp | 0.00% +0.001 pp | USD55.14 +55.2% | 7 qtrs — |
| 21 | ALLIANZ ASSET MANAGEMENT GMBH | 267.6K -27.3K (-9.3%) | 22.90M +5.5M (+31.4%) | 0.74% -0.100 pp | 0.02% +0.004 pp | USD56.00 +52.8% | 3 qtrs — |
| 22 | RAYMOND JAMES FINANCIAL INC | 258.8K +98.6K (+61.6%) | 22.15M +12.7M (+133.8%) | 0.72% +0.259 pp | 0.01% +0.004 pp | USD52.09 +64.3% | 5 qtrs — |
| 23 | JANE STREET GROUP, LLC | 249.6K +38.9K (+18.5%) | 21.36M +8.9M (+71.5%) | 0.69% +0.090 pp | 0.00% +0.001 pp | USD45.74 +87.1% | 6 qtrs — |
| 24 | PERCEPTIVE ADVISORS LLC | 237.3K +237.3K (+100.0%) | 20.31M +20.3M (+100.0%) | 0.66% +0.657 pp | 0.36% +0.362 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 25 | DIMENSIONAL FUND ADVISORS LP | 216.8K +170.1K (+364.7%) | 18.56M +15.8M (+572.7%) | 0.60% +0.467 pp | 0.00% +0.003 pp | USD70.39 +21.6% | 7 qtrs — |
| 26 | UBS GROUP AG | 213.2K -147.3K (-40.9%) | 18.25M -3.1M (-14.4%) | 0.59% -0.438 pp | 0.00% 0.000 pp | USD40.78 +109.9% | 7 qtrs — |
| 27 | CARNEGIE CAPITAL ASSET MANAGEMENT, LLC | 213.1K -32.3K (-13.2%) | 18.23M +3.7M (+25.7%) | 0.59% -0.110 pp | 0.34% +0.063 pp | USD53.92 +58.7% | 3 qtrs — |
| 28 | PRICE T ROWE ASSOCIATES INC /MD/ | 210.8K +179.1K (+564.9%) | 18.04M +16.2M (+862.2%) | 0.58% +0.493 pp | 0.00% +0.002 pp | USD76.24 +12.3% | 7 qtrs — |
| 29 | TCW GROUP INC | 197.3K -35.9K (-15.4%) | 16.89M +3.1M (+22.5%) | 0.55% -0.119 pp | 0.12% +0.006 pp | USD14.01 +510.9% | 7 qtrs — |
| 30 | FMR LLC | 163.2K +54.5K (+50.1%) | 13.97M +7.5M (+117.2%) | 0.45% +0.142 pp | 0.00% +0.000 pp | USD61.07 +40.2% | 7 qtrs — |
| 31 | SLOW CAPITAL, INC. | 162.4K +18.6K (+12.9%) | 13.90M +5.4M (+63.4%) | 0.45% +0.039 pp | 1.66% +0.661 pp | USD25.26 +238.8% | 7 qtrs — |
| 32 | DOUGLAS LANE & ASSOCIATES, LLC | 161.6K -6.7K (-4.0%) | 13.83M +3.9M (+39.0%) | 0.45% -0.033 pp | 0.19% +0.050 pp | USD15.23 +462.0% | 7 qtrs — |
| 33 | BIT CAPITAL GMBH | 156.3K +156.3K (+100.0%) | 13.37M +13.4M (+100.0%) | 0.43% +0.433 pp | 0.49% +0.492 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 34 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 152.6K -52.0 (0.0%) | 13.06M +4.0M (+44.7%) | 0.42% -0.013 pp | 0.05% +0.016 pp | USD28.67 +198.5% | 4 qtrs — |
| 35 | CITADEL ADVISORS LLC | 151.0K +8.9K (+6.2%) | 12.92M +4.5M (+53.8%) | 0.42% +0.013 pp | 0.00% +0.001 pp | USD27.16 +215.1% | 7 qtrs — |
| 36 | NEWTYN MANAGEMENT, LLC | 150.0K -50.0K (-25.0%) | 12.84M +1.0M (+8.6%) | 0.42% -0.155 pp | 1.35% -0.099 pp | USD14.18 +503.6% | 7 qtrs — |
| 37 | VOLEON CAPITAL MANAGEMENT LP | 147.9K +86.3K (+140.2%) | 12.66M +9.0M (+247.7%) | 0.41% +0.234 pp | 0.27% +0.183 pp | USD74.57 +14.8% | 2 qtrs — |
| 38 | FRANKLIN RESOURCES INC | 146.1K +141.5K (+3,072.7%) | 12.51M +12.2M (+4,492.4%) | 0.40% +0.391 pp | 0.00% +0.003 pp | USD84.76 +1.0% | 2 qtrs — |
| 39 | BRAIDWELL LP | 142.8K +142.8K (+100.0%) | 12.22M +12.2M (+100.0%) | 0.40% +0.395 pp | 0.39% +0.391 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 40 | JPMORGAN CHASE & CO | 141.5K -64.6K (-31.4%) | 12.11M -78.8K (-0.6%) | 0.39% -0.196 pp | 0.00% +0.000 pp | USD50.63 +69.0% | 7 qtrs — |
| 41 | INVESCO LTD. | 138.0K +1.4K (+1.0%) | 11.81M +3.7M (+46.3%) | 0.38% -0.008 pp | 0.00% +0.001 pp | USD42.49 +101.4% | 7 qtrs — |
| 42 | BANK OF NEW YORK MELLON CORP | 135.8K +4.9K (+3.7%) | 11.62M +3.9M (+50.2%) | 0.38% +0.003 pp | 0.00% +0.001 pp | USD20.05 +326.9% | 7 qtrs — |
| 43 | BARCLAYS PLC | 125.7K +106.2K (+545.2%) | 10.76M +10.5M (+3,913.2%) | 0.35% +0.292 pp | 0.00% +0.003 pp | USD78.95 +8.4% | 7 qtrs — |
| 44 | ABRDN PLC | 124.9K -144.5K (-53.6%) | 10.69M -5.2M (-32.9%) | 0.35% -0.423 pp | 0.02% -0.009 pp | USD26.23 +226.3% | 7 qtrs — |
| 45 | D. E. SHAW & CO., INC. | 120.1K +38.6K (+47.4%) | 10.28M +5.5M (+113.3%) | 0.33% +0.100 pp | 0.01% +0.003 pp | USD57.58 +48.6% | 4 qtrs — |
| 46 | 180 WEALTH ADVISORS, LLC | 115.0K -3.8K (-3.2%) | 9.85M +2.8M (+40.1%) | 0.32% -0.021 pp | 1.12% +0.265 pp | USD21.12 +305.3% | 6 qtrs — |
| 47 | CAPITAL FUND MANAGEMENT S.A. | 113.2K -62.0K (-35.4%) | 9.69M -671.4K (-6.5%) | 0.31% -0.187 pp | 0.03% 0.000 pp | USD57.21 +49.6% | 3 qtrs — |
| 48 | REYNDERS MCVEIGH CAPITAL MANAGEMENT, LLC | 112.9K -7.7K (-6.4%) | 9.66M +2.5M (+35.5%) | 0.31% -0.032 pp | 0.45% +0.119 pp | USD21.19 +303.9% | 6 qtrs — |
| 49 | FIRST TRUST ADVISORS LP | 108.3K +108.3K (+100.0%) | 9.27M +9.3M (+100.0%) | 0.30% +0.300 pp | 0.01% +0.007 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 50 | WIM INVESTMENT MANAGEMENT LTD | 106.4K +43.4K (+68.9%) | 9.11M +5.4M (+144.5%) | 0.29% +0.115 pp | 2.35% +1.406 pp | USD60.97 +40.4% | 6 qtrs — |
| 51 | TWO SIGMA INVESTMENTS, LP | 101.4K -45.6K (-31.0%) | 8.68M -11.0K (-0.1%) | 0.28% -0.139 pp | 0.01% -0.001 pp | USD22.75 +276.2% | 5 qtrs — |
| 52 | BLUE WATER LIFE SCIENCE ADVISORS, LP | 99.0K +99.0K (+100.0%) | 8.47M +8.5M (+100.0%) | 0.27% +0.274 pp | 5.32% +5.318 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 53 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 86.6K +86.6K (+100.0%) | 7.41M +7.4M (+100.0%) | 0.21% +0.213 pp | 0.00% +0.005 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 54 | RENAISSANCE TECHNOLOGIES LLC | 85.3K -17.8K (-17.3%) | 7.30M +1.2M (+19.8%) | 0.24% -0.058 pp | 0.01% +0.003 pp | USD51.42 +66.5% | 3 qtrs — |
| 55 | AMERICAN CENTURY COMPANIES INC | 81.5K +15.1K (+22.7%) | 6.97M +3.0M (+77.6%) | 0.23% +0.036 pp | 0.00% +0.002 pp | USD53.24 +60.8% | 6 qtrs — |
| 56 | SWISS NATIONAL BANK | 72.3K +13.0K (+21.9%) | 6.19M +2.7M (+76.5%) | 0.20% +0.031 pp | 0.00% +0.002 pp | USD29.28 +192.3% | 7 qtrs — |
| 57 | NUVEEN, LLC | 70.9K +3.2K (+4.8%) | 6.06M +2.1M (+51.6%) | 0.20% +0.003 pp | 0.00% +0.001 pp | USD30.93 +176.7% | 4 qtrs — |
| 58 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 68.6K +10.6K (+18.2%) | 5.87M +2.4M (+71.1%) | 0.19% +0.024 pp | 0.01% +0.004 pp | USD27.57 +210.4% | 7 qtrs — |
| 59 | LEGAL & GENERAL GROUP PLC | 68.3K +1.3K (+2.0%) | 5.85M +1.9M (+47.6%) | 0.19% -0.002 pp | 0.00% +0.000 pp | USD23.82 +259.3% | 7 qtrs — |
| 60 | CITIGROUP INC | 67.5K +17.8K (+35.9%) | 5.78M +2.8M (+96.7%) | 0.19% +0.045 pp | 0.00% +0.001 pp | USD38.86 +120.3% | 7 qtrs — |
| 61 | WELLS FARGO & COMPANY/MN | 65.3K +11.1K (+20.5%) | 5.59M +2.4M (+74.5%) | 0.18% +0.026 pp | 0.00% +0.000 pp | USD57.46 +49.0% | 7 qtrs — |
| 62 | UBS ASSET MANAGEMENT AMERICAS INC | 61.6K +2.5K (+4.2%) | 5.27M +1.8M (+50.8%) | 0.17% +0.002 pp | 0.00% +0.000 pp | USD23.25 +268.1% | 7 qtrs — |
| 63 | RAFFERTY ASSET MANAGEMENT, LLC | 61.3K +18.3K (+42.5%) | 5.25M +2.7M (+106.3%) | 0.17% +0.047 pp | 0.02% +0.010 pp | USD39.80 +115.1% | 7 qtrs — |
| 64 | PEAK6 LLC | 56.8K +31.3K (+122.7%) | 4.86M +3.4M (+222.4%) | 0.16% +0.085 pp | 0.01% +0.007 pp | USD73.71 +16.1% | 2 qtrs — |
| 65 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 55.9K +55.9K (+100.0%) | 4.78M +4.8M (+100.0%) | 0.15% +0.155 pp | 0.02% +0.016 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 66 | ROYAL BANK OF CANADA | 54.3K -7.4K (-12.0%) | 4.65M +1.0M (+27.4%) | 0.15% -0.026 pp | 0.00% +0.000 pp | USD16.29 +425.4% | 7 qtrs — |
| 67 | PIER CAPITAL, LLC | 51.8K -53.7K (-50.9%) | 4.44M -1.8M (-28.9%) | 0.14% -0.158 pp | 0.71% -0.267 pp | USD51.42 +66.5% | 3 qtrs — |
| 68 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 50.5K +50.5K (+100.0%) | 4.32M +4.3M (+100.0%) | 0.14% +0.140 pp | 0.19% +0.185 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 69 | VERITION FUND MANAGEMENT LLC | 47.5K +16.6K (+53.4%) | 4.07M +2.2M (+122.1%) | 0.13% +0.043 pp | 0.02% +0.008 pp | USD68.35 +25.2% | 2 qtrs — |
| 70 | RHUMBLINE ADVISERS | 47.1K -1.4K (-3.0%) | 4.03M +1.2M (+40.4%) | 0.13% -0.008 pp | 0.00% +0.001 pp | USD32.77 +161.2% | 7 qtrs — |
| 71 | GILDER GAGNON HOWE & CO LLC | 43.7K +26.2K (+149.9%) | 3.74M +2.7M (+261.7%) | 0.12% +0.071 pp | 0.04% +0.029 pp | USD72.79 +17.6% | 3 qtrs — |
| 72 | PICTET ASSET MANAGEMENT HOLDING SA | 40.9K +37.3K (+1,036.8%) | 3.58M +3.4M (+1,584.0%) | 0.11% +0.103 pp | 0.00% +0.003 pp | USD82.58 +3.6% | 3 qtrs — |
| 73 | AMERIPRISE FINANCIAL INC | 41.0K +30.5K (+290.9%) | 3.51M +2.9M (+465.8%) | 0.11% +0.084 pp | 0.00% +0.001 pp | USD73.70 +16.1% | 7 qtrs — |
| 74 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 38.5K +38.5K (+100.0%) | 3.29M +3.3M (+100.0%) | 0.11% +0.107 pp | 0.01% +0.006 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 75 | ALLIANCEBERNSTEIN L.P. | 38.4K +1.8K (+4.8%) | 3.28M +1.1M (+51.8%) | 0.11% +0.002 pp | 0.00% +0.000 pp | USD41.19 +107.8% | 7 qtrs — |
| 76 | VICTORY CAPITAL MANAGEMENT INC | 37.8K +9.8K (+35.2%) | 3.23M +1.6M (+95.8%) | 0.10% +0.025 pp | 0.00% +0.001 pp | USD66.03 +29.6% | 2 qtrs — |
| 77 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 30.9K +366.0 (+1.2%) | 3.21M +1.3M (+67.5%) | 0.09% -0.002 pp | 0.00% +0.002 pp | USD30.76 +178.3% | 4 qtrs — |
| 78 | STIFEL FINANCIAL CORP | 37.4K -10.9K (-22.6%) | 3.20M +344.2K (+12.1%) | 0.10% -0.034 pp | 0.00% +0.000 pp | USD29.48 +190.3% | 6 qtrs — |
| 79 | LPL FINANCIAL LLC | 36.0K -10.1K (-21.8%) | 3.08M +357.9K (+13.1%) | 0.10% -0.032 pp | 0.00% +0.000 pp | USD44.00 +94.5% | 6 qtrs — |
| 80 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 34.8K +5.2K (+17.4%) | 2.98M +1.2M (+70.0%) | 0.10% +0.012 pp | 0.00% +0.001 pp | USD28.82 +197.0% | 7 qtrs — |
| 81 | LEGAL ADVANTAGE INVESTMENTS, INC. | 33.5K +12.5K (+59.5%) | 2.87M +1.6M (+130.9%) | 0.09% +0.033 pp | 1.33% +0.768 pp | USD69.00 +24.0% | 4 qtrs — |
| 82 | JACKSON HOLE CAPITAL PARTNERS, LLC | 33.0K +— (+0.0%) | 2.82M +873.2K (+44.7%) | 0.09% -0.003 pp | 0.48% +0.150 pp | USD13.76 +522.0% | 6 qtrs — |
| 83 | GABELLI FUNDS LLC | 31.7K -2.8K (-8.2%) | 2.71M +670.5K (+32.9%) | 0.09% -0.011 pp | 0.02% +0.005 pp | USD18.19 +370.5% | 7 qtrs — |
| 84 | BAIRD FINANCIAL GROUP, INC. | 31.1K +31.1K (+100.0%) | 2.66M +2.7M (+100.0%) | 0.09% +0.086 pp | 0.00% +0.004 pp | USD85.59 +0.0% | 1 qtrs NEW |
| 85 | CATALIO CAPITAL MANAGEMENT, LP | 30.3K -107.6K (-78.0%) | 2.59M -5.6M (-68.2%) | 0.08% -0.310 pp | 0.46% -1.049 pp | USD59.13 +44.7% | 2 qtrs — |
| 86 | MILLENNIUM MANAGEMENT LLC | 30.0K -78.2K (-72.3%) | 2.57M -3.8M (-59.9%) | 0.08% -0.226 pp | 0.00% -0.002 pp | USD54.47 +57.1% | 4 qtrs — |
| 87 | EAM INVESTORS, LLC | 29.7K +29.7K (+100.0%) | 2.54M +2.5M (+100.0%) | 0.08% +0.082 pp | 0.28% +0.283 pp | USD85.59 +0.0% | 4 qtrs — |
| 88 | ADVISOR GROUP HOLDINGS, INC. | 29.3K -1.1K (-3.5%) | 2.50M +1.4M (+133.3%) | 0.08% -0.006 pp | 0.00% +0.002 pp | USD48.88 +75.1% | 7 qtrs — |
| 89 | MUTUAL ADVISORS, LLC | 29.1K -441.0 (-1.5%) | 2.49M +49.2K (+2.0%) | 0.08% -0.004 pp | 0.05% 0.000 pp | USD59.13 +44.7% | 2 qtrs — |
| 90 | IEQ CAPITAL, LLC | 28.5K -970.0 (-3.3%) | 2.44M +697.3K (+40.0%) | 0.08% -0.005 pp | 0.01% +0.002 pp | USD35.87 +138.6% | 5 qtrs — |
| 91 | DEUTSCHE BANK AG\ | 28.5K +1.7K (+6.2%) | 2.44M +853.0K (+53.7%) | 0.08% +0.002 pp | 0.00% +0.000 pp | USD35.67 +139.9% | 7 qtrs — |
| 92 | TUDOR INVESTMENT CORP ET AL | 28.5K -18.8K (-39.7%) | 2.44M -355.9K (-12.8%) | 0.08% -0.056 pp | 0.00% 0.000 pp | USD15.64 +447.3% | 6 qtrs — |
| 93 | VAN ECK ASSOCIATES CORP | 27.5K +760.0 (+2.8%) | 2.36M +774.0K (+48.9%) | 0.08% 0.000 pp | 0.00% +0.001 pp | USD20.12 +325.4% | 7 qtrs — |
| 94 | COMMERCE BANK | 26.9K -1.6K (-5.6%) | 2.30M +616.7K (+36.6%) | 0.07% -0.007 pp | 0.01% +0.003 pp | USD53.94 +58.7% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 103 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Clough Select Equity ETF CBSE | 2.55% | 1.42M | 0.85% |
| 2 | Franklin Genomic Advancements ETF HELX | 1.14% | 343.7K | 0.50% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.95% | 341.7K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.95% | 102.92M | 0.35% |
| 5 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.32% | 3.71M | 0.40% |
| 6 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.22% | 6.25M | 0.34% |
| 7 | iShares Biotechnology ETF IBB | 0.22% | 20.61M | 0.44% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.21% | 983.4K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.21% | 158.7K | 0.19% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.21% | 155.5K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
0.01
Bearish
Buys
3
Sells
3
Shares acquired
1.4K
Shares disposed
231.0K
Cash buys
—
Cash sales
3.00
Net activity
-229,538
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | SUMME GREGORY L | Director | A-Award | A | Common Stock | 631 | 49.79 | 31.4K | 39,754 | D | ↗ |
| 2026-04-15 | MIZELL STEVEN | Director | A-Award | A | Common Stock | 396 | 49.79 | 19.7K | 37,071 | D | ↗ |
| 2026-04-15 | CHASE WILLIAM J | Director | A-Award | A | Common Stock | 408 | 49.79 | 20.3K | 37,211 | D | ↗ |
| 2026-04-08 | RAGUSA ROBERT P | Director / Officer | S-Sale | D | Common Stock | 123,502 | 49.92 | 6.16M | 518,582 | D | ↗ |
| 2026-04-08 | Ofman Joshua J. | Director / Officer | S-Sale | D | Common Stock | 61,665 | 49.92 | 3.08M | 371,216 | D | ↗ |
| 2026-04-08 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 45,806 | 49.92 | 2.29M | 260,669 | D | ↗ |
| 2026-03-09 | RAGUSA ROBERT P | Director / Officer | S-Sale | D | Common Stock | 258 | 46.73 | 12.1K | 642,084 | D | ↗ |
| 2026-03-09 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 2,836 | 47.93 | 135.9K | 432,982 | D | ↗ |
| 2026-03-09 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 2,407 | 47.93 | 115.4K | 306,560 | D | ↗ |
| 2026-03-05 | RAGUSA ROBERT P | Director / Officer | S-Sale | D | Common Stock | 980 | 53.01 | 51.9K | 649,545 | D | ↗ |
| 2026-03-05 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 690 | 53.01 | 36.6K | 435,818 | D | ↗ |
| 2026-03-05 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 655 | 53.01 | 34.7K | 308,967 | D | ↗ |
| 2026-03-02 | RAGUSA ROBERT P | Director / Officer | S-Sale | D | Common Stock | 1,717 | 51.84 | 89.0K | 650,525 | D | ↗ |
| 2026-03-02 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 779 | 51.75 | 40.3K | 452,731 | D | ↗ |
| 2026-03-02 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 438 | 51.86 | 22.7K | 309,622 | D | ↗ |
| 2026-02-27 | Ofman Joshua J. | Officer | A-Award | A | Common Stock | 84,540 | 53.23 | 4.50M | 453,510 | D | ↗ |
| 2026-02-27 | Freidin Aaron | Officer | A-Award | A | Common Stock | 60,118 | 53.23 | 3.20M | 319,195 | D | ↗ |
| 2026-01-15 | SUMME GREGORY L | Director | A-Award | A | Common Stock | 329 | 97.44 | 32.1K | 39,123 | D | ↗ |
| 2026-01-15 | MIZELL STEVEN | Director | A-Award | A | Common Stock | 206 | 97.44 | 20.1K | 36,675 | D | ↗ |
| 2026-01-15 | CHASE WILLIAM J | Director | A-Award | A | Common Stock | 213 | 97.44 | 20.8K | 36,803 | D | ↗ |
| 2025-12-03 | RAGUSA ROBERT P | Director / Officer | S-Sale | D | Common Stock | 14,807 | 94.43 | 1.40M | 713,222 | D | ↗ |
| 2025-12-03 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 13,000 | 100.00 | 1.30M | 368,818 | D | ↗ |
| 2025-12-03 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 25,000 | 99.15 | 2.48M | 259,077 | D | ↗ |
| 2025-11-17 | ILLUMINA, INC. | 10% Owner | S-Sale | D | Common stock, par value $0.001 per share | 1,000,000 | 79.85 | 79.85M | 3,502,126 | D | ↗ |
| 2025-11-17 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 1,697 | 79.20 | 134.4K | 284,077 | D | ↗ |
| 2025-10-16 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 6,114 | 82.01 | 501.4K | 381,818 | D | ↗ |
| 2025-10-15 | SUMME GREGORY L | Director | A-Award | A | Common Stock | 425 | 75.52 | 32.1K | 38,794 | D | ↗ |
| 2025-10-15 | RAGUSA ROBERT P | Director / Officer | S-Sale | D | Common Stock | 7,239 | 68.88 | 498.6K | 727,388 | D | ↗ |
| 2025-10-15 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 8,865 | 76.03 | 674.0K | 387,932 | D | ↗ |
| 2025-10-15 | MIZELL STEVEN | Director | A-Award | A | Common Stock | 267 | 75.52 | 20.2K | 36,469 | D | ↗ |
| 2025-10-15 | CHASE WILLIAM J | Director | A-Award | A | Common Stock | 275 | 75.52 | 20.8K | 36,590 | D | ↗ |
| 2025-10-06 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 81,385 | 62.50 | 5.09M | 396,797 | D | ↗ |
| 2025-10-02 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 9,692 | 64.00 | 620.3K | 478,182 | D | ↗ |
| 2025-08-19 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 4,202 | 32.02 | 134.5K | 487,874 | D | ↗ |
| 2025-08-19 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 877 | 32.02 | 28.1K | 285,143 | D | ↗ |
| 2025-07-15 | SUMME GREGORY L | Director | A-Award | A | Common Stock | 825 | 38.53 | 31.8K | 38,369 | D | ↗ |
| 2025-07-15 | MIZELL STEVEN | Director | A-Award | A | Common Stock | 517 | 38.53 | 19.9K | 36,202 | D | ↗ |
| 2025-07-15 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 8,000 | 38.93 | 311.4K | 286,020 | D | ↗ |
| 2025-07-15 | CHASE WILLIAM J | Director | A-Award | A | Common Stock | 533 | 38.53 | 20.5K | 36,315 | D | ↗ |
| 2025-07-01 | DING CHUN R | 10% Owner | S-Sale | D | Common Stock | 27,843 | 50.25 | 1.40M | 3,305,055 | I | ↗ |
| 2025-06-30 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 9,692 | 52.00 | 504.0K | 492,076 | D | ↗ |
| 2025-06-12 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 9,692 | 42.30 | 410.0K | 501,768 | D | ↗ |
| 2025-05-29 | SUMME GREGORY L | Director | A-Award | A | Common Stock | 6,082 | 41.10 | 250.0K | 37,544 | D | ↗ |
| 2025-05-29 | MIZELL STEVEN | Director | A-Award | A | Common Stock | 6,082 | 41.10 | 250.0K | 35,685 | D | ↗ |
| 2025-05-29 | Krevans Sarah | Director | A-Award | A | Common Stock | 6,082 | 41.10 | 250.0K | 37,137 | D | ↗ |
| 2025-05-29 | CHASE WILLIAM J | Director | A-Award | A | Common Stock | 6,082 | 41.10 | 250.0K | 35,782 | D | ↗ |
| 2025-05-02 | RAGUSA ROBERT P | Director / Officer | S-Sale | D | Common Stock | 94,035 | 33.93 | 3.19M | 734,627 | D | ↗ |
| 2025-05-02 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 48,213 | 33.93 | 1.64M | 511,460 | D | ↗ |
| 2025-05-02 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 41,150 | 33.93 | 1.40M | 294,020 | D | ↗ |
| 2025-04-15 | SUMME GREGORY L | Director | A-Award | A | Common Stock | 1,212 | 25.94 | 31.4K | 31,462 | D | ↗ |
| 2025-04-15 | MIZELL STEVEN | Director | A-Award | A | Common Stock | 760 | 25.94 | 19.7K | 29,603 | D | ↗ |
| 2025-04-15 | CHASE WILLIAM J | Director | A-Award | A | Common Stock | 784 | 25.94 | 20.3K | 29,700 | D | ↗ |
| 2025-03-11 | RAGUSA ROBERT P | Director / Officer | S-Sale | D | Common Stock | 7,625 | 31.21 | 238.0K | 828,662 | D | ↗ |
| 2025-03-11 | Ofman Joshua J. | Officer | S-Sale | D | Common Stock | 2,109 | 31.20 | 65.8K | 559,673 | D | ↗ |
| 2025-03-11 | Freidin Aaron | Officer | S-Sale | D | Common Stock | 1,816 | 31.20 | 56.7K | 335,170 | D | ↗ |
| 2024-06-24 | ILLUMINA, INC. | 10% Owner | J-Other | D | Common stock, par value $0.001 per share | 26,547,021 | 0.00 | — | 4,502,126 | — | ↗ |
| 2024-06-03 | ILLUMINA, INC. | 10% Owner | — | D | Membership Interests of GRAIL, LLC | 0 | 0.00 | — | 100 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.9K
Shares Outstanding
41.02M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Robert Ragusa Chief Executive Officer | 785.0K | — | 6.48M | — | 778.1K | 53.3K | 8.09M | 80.03% | ↗ |
| 2 | 2025 | Joshua Ofman President | 655.0K | — | 3.19M | — | 376.6K | 92.4K | 4.32M | 73.97% | ↗ |
| 3 | 2025 | Aaron Freidin Chief Financial Officer | 560.0K | 250.0K | 2.00M | — | 321.9K | 3.0K | 3.13M | 63.76% | ↗ |
| 4 | 2024 | Robert Ragusa Chief Executive Officer | 785.0K | — | 6.07M | — | 714.4K | 40.4K | 7.61M | 79.76% | ↗ |
| 5 | 2024 | Joshua Ofman President | 655.0K | — | 4.77M | — | 298.0K | 87.8K | 5.81M | 82.07% | ↗ |
| 6 | 2024 | Josh Ofman President | 655.0K | — | 4.77M | — | 298.0K | 87.8K | 5.81M | 82.07% | ↗ |
| 7 | 2024 | Aaron Freidin Chief Financial Officer | 560.0K | — | 2.88M | — | 254.8K | 3.0K | 3.69M | 77.85% | ↗ |
| 8 | 2023 | Robert Ragusa Chief Executive Officer | 779.6K | — | 8.40M | — | 678.9K | 19.7K | 9.88M | 85.04% | ↗ |
| 9 | 2023 | Josh Ofman President | 654.2K | — | 3.30M | — | 283.5K | 99.1K | 4.34M | 76.09% | ↗ |
| 10 | 2023 | Aaron Freidin Chief Financial Officer | 556.2K | — | 2.80M | — | 242.2K | 3.0K | 3.60M | 77.75% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Ragusa | Chief Executive Officer & Director | 2M | male |
| Aaron Freidin | Chief Financial Officer | 1M | male |
| Joshua J. Ofman | President & Director | 1M | — |
| Alison Highlander | Senior Vice President of Human Resources & Head of People Team | — | female |
| Andrew John Partridge | Chief Commercial Officer | — | male |
| Eric T. Fung | Senior Vice President of Clinical Development | — | — |
| Erin Polak | Senior Vice President of Government Affairs, Policy, and Alliance Development | — | female |
| Linda J. Peters | Senior Vice President of Quality & Regulatory | — | female |
| Paul Ciccolella | Senior Vice President of Global Development & Operations | — | male |
| Satnam Alag | Senior Vice President of Software Engineering & Chief Security Officer | — | — |
| Sir Harpal S. Kumar | Chief Scientific Officer & President International | — | — |
| Abram Barth | General Counsel & Corporate Secretary | — | male |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GRAL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
